E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The myeloproliferative disorders (MPDs) polycythaemia vera (PV) and essential thrombocythaemia (ET) are chronic haematological malignancies associated with increased risk of thrombosis, haemorrhage and leukaemic transformation. Recently an acquired mutation in JAK 2 has been described in >95% of patients with PV and 50% with ET. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this trial is to evaluate the safety and efficacy of Vorinostat in patients with advanced, refractory of resistant Polycythaemia Vera and Essential Thrombocythaemia and in those intolerant to other therapies.
The main objectives are:
1. To evaluate the safety and efficacy of a maximum of 6 months therapy with vorinostat in the treatment of patients with advanced, refractory or resistant polycythaemia vera (PV) and essential thrombocythaemia (ET) or in those intolerant of other therapies. 2. To evaluate if vorinostat as monotherapy of patients with PV and ET is followed by a decline in clonal myeloproliferation as assessed by conventional disease activity parameteres (a decrease in the need of phlebotomy, leucocyte and platelet count). 3. To investigate whether treatment with vorinostat influences the JAK2 mutation status as assessed by quantitative PCR. |
|
E.2.2 | Secondary objectives of the trial |
1. To study changes in bone marrow morphology before and after treatment with vorinostat. 2. To investigate whether treatment with vorinostat influences the JAK2 mutation status as assessed by quantitative PCR. 3. To perform integrated gene expression (global and focused) profiling, epigenome profiling and proteome studies (serum-based) before and during treatment with vorinostat in order to describe in detail the various (heterogeneous) response patterns at the molecular level. 4. To study immune cells and function (dendritic cells, regulatory T-cells, NK-cells and specific T-cell responses) before and during treatment with vorinostat. 5. To study in vivo granulocyte, platelet and endothelial activation before and during treatment with vorinostat. 6. To evaluate the safety of vorinostat in the treatment of patients with polycythaemia vera (PV) and essential thrombocythaemia (ET).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria for PV 1. Male or female patient > 18 years of age and 2. A confirmed diagnosis of PV (see appendix 1) and 3. Biochemical evidence of active disease as defined by a) A need for phlebotomy within the last 3 months b) a leukocyte count > 10 x 109/L in the absence of infection or inflammation (normal CRP) and/or (PV/ET) c) a platelet count > 450 x 109/L in the absence of infection or inflammation (normal CRP) (PV/ET). 8.1b. Inclusion Criteria for ET 1. Male or female patient > 18 years of age and 2. A confirmed diagnosis of high risk ET (see appendix 1) and 3. Biochemical evidence of active disease as defined by a) a platelet count > 450 x 109/L in the absence of infection or inflammation (normal CRP). 8.1c. Inclusion Criteria for both PV and ET 1. Newly diagnosed or previously treated patients in chronic phase or 2. Advanced phase PV or ET as defined by blasts of > 1 x 109/L in the peripheral blood and/or white cell count> 30 x 109/L or 3. Resistant or refractory PV or ET as defined by a haemoglobin< 10.5gm/dl with a platelet count >600 x 109/L on current therapy or 4. Cycling platelet counts on therapy or 5.Intolerant to other therapies defined by patients with PV or ET who have side effects on current therapies preventing continuation (leg ulcers on hydroxycarbamide, unacceptable fatigue etc on interferon).
|
|
E.4 | Principal exclusion criteria |
1. A platelet count > 1500 x 109/L (a need for cytoreduction in platelet count) 2. Patients of childbearing potential without a negative pregnancy test prior to initiation of study drug. 3. Women who are breast feeding 4. Males and females not using contraceptives if sexually active. It is recommended that 2 reliable forms of contraception be used simultaneously unless abstinence is the chosen method of contraception. Non-pregnant, non-breast-feeding women may be enrolled if they are considered highly unlikely to conceive. Highly unlikely to conceive is defined as (a) surgically sterilized, or (b) postmenopausal, or (c) not heterosexually active for the duration of the study, or (d) heterosexually active and willing to use 2 birth control methods. The 2 birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy, used throughout the study starting with Visit 1. A woman who is ≥45 years of age and has not had menses for greater than 2 years will be considered postmenopausal. 5. ECOG Performance Status Score ≥ 3 6. Serum creatinine more than 2 x’s the ULN 7. Total serum bilirubin more than 1.5 x’s the ULN 8. Serum AST/ALT more than 3 x’s the ULN 9. Interferon alpha within 1 week of day 1 10. Hydroxycarbamide within 1 week of day 1 11. Anagrelide within 1 week of day 1 12. Valproic acid (as an anticonvulsant) within 28 days of day 1 13. Any other investigational drug within 28 days of day 1 14. Active HIV, HBV or HCV infection 15. Any serious concomitant disease or circumstances that could limit compliance with the study, including but not limited to the following: CTCAE grade 3-4 cardiac general & arrhythmia, or psychiatric or social conditions that may interfere with patient compliance. 16. Any prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed to be at low risk for recurrence by his/her treating physician 17. Patient has a known allergy or hypersensitivity to vorinostat capsules
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Complete Response: Pts <= 400 x 10 9/L and no disease-related symptoms and normal spleen size on imaging nad WBC count <= 10 x 10 9/L
Partial Response: No CR and pts below 600 x 10 9/L or a decrease in patients > 50% of base line value |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Information not present in EudraCT |
E.6.5 | Efficacy | Information not present in EudraCT |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |